Literature DB >> 25664076

Increased hepatocyte growth factor and c-Met receptor expression in nasopharyngeal carcinoma.

Tian Luan1, Yang Yu2.   

Abstract

Hepatocyte growth factor (HGF) and its receptor, c-Met, are associated with invasive tumor growth. This study sought to profile the expression of HGF and c-Met in nasopharyngeal carcinoma (NPC) tissue. Of 221 patients recruited between March 2010 and September 2013, 106 were diagnosed with nasopharyngeal carcinoma; the remaining 115 had nasal inflammation (nasopharyngeal mucositis) and were used as controls. Inmmunohistochemistry was used to detect the expression of HGF and c-Met in tissue samples. HGF and c-Met were predominantly expressed in the columnar nasopharyngeal epithelium. The proportion of samples expressing HGF and c-Met was significantly higher in NPC than in controls (P < 0.001). Further, the proportion of samples expressing c-Met and HGF (P < 0.01, P < 0.05, respectively) was significantly higher in NPC stages III and IV than in stages I and II. The expression of c-Met was also significantly correlated with cervical lymph node metastasis. Thus, HGF and c-Met expression are upregulated in nasopharyngeal carcinoma. That their expression correlates with disease severity and metastasis may indicate that these proteins promote tumor invasion. Further research could determine the utility of c-Met as a biomarker for the prognosis of NPC.

Entities:  

Keywords:  Nasopharyngeal carcinoma; c-Met; hepatocyte growth factor; immunohistochemistry

Year:  2014        PMID: 25664076      PMCID: PMC4307523     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  15 in total

Review 1.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

2.  Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma.

Authors:  Chao-Nan Qian; Xiang Guo; Brian Cao; Eric J Kort; Chong-Chou Lee; Jindong Chen; Ling-Mei Wang; Wei-Yuan Mai; Hua-Qing Min; Ming-Huang Hong; George F Vande Woude; James H Resau; Bin Tean Teh
Journal:  Cancer Res       Date:  2002-01-15       Impact factor: 12.701

3.  Silencing of c-Met by RNA interference inhibits the survival, proliferation, and invasion of nasopharyngeal carcinoma cells.

Authors:  Yuncheng Li; Sulin Zhang; Zhengang Tang; Jian Chen; Weijia Kong
Journal:  Tumour Biol       Date:  2011-09-16

4.  Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.

Authors:  Yuji Toiyama; Hiromi Yasuda; Susumu Saigusa; Kouhei Matushita; Hiroyuki Fujikawa; Koji Tanaka; Yasuhiko Mohri; Yasuhiro Inoue; Ajay Goel; Masato Kusunoki
Journal:  Int J Cancer       Date:  2011-09-12       Impact factor: 7.396

5.  Altered expression of E-cadherin by hepatocyte growth factor and effect on the prognosis of nasopharyngeal carcinoma.

Authors:  Li-qiong Xie; Li-juan Bian; Zhi Li; Yang Li; Zhi-xun Li; Bin Li
Journal:  Ann Surg Oncol       Date:  2010-02-04       Impact factor: 5.344

Review 6.  The role of signaling pathways in the development and treatment of hepatocellular carcinoma.

Authors:  S Whittaker; R Marais; A X Zhu
Journal:  Oncogene       Date:  2010-07-19       Impact factor: 9.867

7.  Co-elevated expression of hepatocyte growth factor and Interleukin-8 contributes to poor prognosis of patients with primary nasopharyngeal carcinoma.

Authors:  Li-Qiong Xie; Li-Juan Bian; Zhi Li; Yang Li; Ying-Jie Liang
Journal:  Oncol Rep       Date:  2010-01       Impact factor: 3.906

8.  HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.

Authors:  Lynn M Knowles; Laura P Stabile; Ann Marie Egloff; Mary E Rothstein; Sufi M Thomas; Christopher T Gubish; Edwina C Lerner; Raja R Seethala; Shinsuke Suzuki; Kelly M Quesnelle; Sarah Morgan; Robert L Ferris; Jennifer R Grandis; Jill M Siegfried
Journal:  Clin Cancer Res       Date:  2009-05-26       Impact factor: 12.531

Review 9.  Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.

Authors:  Xiangdong Liu; Robert C Newton; Peggy A Scherle
Journal:  Trends Mol Med       Date:  2009-12-22       Impact factor: 11.951

10.  c-Met signaling promotes IL-6-induced myeloma cell proliferation.

Authors:  Håkon Hov; Erming Tian; Toril Holien; Randi Utne Holt; Thea K Våtsveen; Unn-Merete Fagerli; Anders Waage; Magne Børset; Anders Sundan
Journal:  Eur J Haematol       Date:  2009-01-06       Impact factor: 2.997

View more
  2 in total

1.  Met inactivation by S-allylcysteine suppresses the migration and invasion of nasopharyngeal cancer cells induced by hepatocyte growth factor.

Authors:  Oyeon Cho; Hye-Sook Hwang; Bok-Soon Lee; Young-Taek Oh; Chul-Ho Kim; Mison Chun
Journal:  Radiat Oncol J       Date:  2015-12-30

2.  High expression of c-Met and EGFR is associated with poor survival of patients with glottic laryngeal squamous cell carcinoma.

Authors:  Mei Jiang; Hui Zhang; He Xiao; Zhimin Zhang; Dan Que; Jia Luo; Jian Li; Bijing Mao; Yuanyuan Chen; Meilin Lan; Ge Wang; Hualiang Xiao
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.